Welcome to Iressa.com
In Europe, IRESSA (gefitinib) is indicated for the treatment of adults with locally advanced or metastatic NSCLC with activating mutations of EGFR-TK across all lines of therapy.
-
WELCOME TO IRESSA INTERNATIONAL WEBSITE :
The site is intended for an international audience of healthcare professionals, please continue visiting IRESSA international website.
If you are a patient, you should visit the Patient Health International site.
If you are a journalist, you should visit the AstraZeneca Press Office.
-
LOCAL HEALTHCARE PROFESSIONAL WEBSITES:
- If you are a healthcare professional in the United States, you should visit Iressa US
- If you are a healthcare professional in the United Kingdom, you should visit the AstraZeneca UK website
- If you are a healthcare professional in Germany, you should visit Lungenkrebs website
- If you are a healthcare professional in China, you should visit Iressa China
(如果您是中国的医疗专业人士，请访问“易瑞沙中国网站”)
AstraZeneca Pharmaceuticals is committed to high standards of information provision. This site has been prepared for a global audience with reference to the IFPMA code of marketing practices and the Health on the Net code, as well as our high company standards.
Should you have any questions or concerns about this site please contact: infomaster@astrazeneca.com.
